Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation

  • Discussing how LCB’s sitespecific ConjuAllTM platform enables discrete DAR ADCs with circulation stable bioconjugation
  • Leveraging LCB’s proprietary beta-glucuronidase technology to enable unprecedented preclinical therapeutic indexes through tumor selective release and payload activation
  • Assessing early clinical safety and efficacy across payload classes to validate the LCB platform